Rett syndrome
About
Rett syndrome is caused by a mutation in the MECP2 gene, is X-linked dominant inheritance, and mainly affects girls. The child developed normally for 6-18 months after birth, and then experienced development regression and lost language and motor skills. Core dilemmas: ① There is currently no effective treatment method to reverse nerve damage;② Although Trofinetide has been approved, its effect is limited;③ Gene therapy is in early clinical trials.
Features & Symptoms
- MECP2 gene mutation
- X-linked dominant inheritance
- Disease in girls
- Loss of speech and motor skills
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| Trofinetide（Daybue） | The IGF-1 analogue, approved by the FDA in 2023, is the first approved treatment for Rett syndrome and improves some symptoms. | FDA批准 | $400K - $800K/年 |
| Gene therapy (AAV-MECP2) | The AAV vector delivers the normal MECP2 gene and is currently in clinical trials. | Phase I/II | $1M - $3M/次（一次性） |
| Comprehensive rehabilitation management | Including comprehensive programs such as physical therapy, occupational therapy, speech therapy, nutritional support, and epilepsy management. | 临床应用 | $100K - $250K/年 |
Prognosis
Survive into adulthood, but severely disabled
Additional Notes
Notes: Early intervention: Early diagnosis and intervention can improve prognosis, focusing on communication training and exercise rehabilitation; Epilepsy management: About 80% of patients with Rett syndrome will develop epilepsy and require standardized anti-epileptic treatment; Bone management: Increased risk of osteoporosis and fractures requires calcium supplementation and vitamin D and regular bone mineral density checks; Nutritional support: Patients with difficulty eating through oral may require gastrostomy nutritional support;Trofinetide: has been approved for Rett syndrome to improve communication and behavioral symptoms.; Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Study phase: FDA approval. Prognosis: Survive into adulthood, but severely disabled.
Frequently Asked Questions
What is Rett syndrome?
Rett syndrome is caused by a mutation in the MECP2 gene, is X-linked dominant inheritance, and mainly affects girls. The child developed normally for 6-18 months after birth, and then experienced development regression and lost language and motor skills. Core dilemmas: ① There is currently no effective treatment method to reverse nerve damage;② Although Trofinetide has been approved, its effect is limited;③ Gene therapy is in early clinical trials.
What are the symptoms of Rett syndrome?
MECP2 gene mutation,X-linked dominant inheritance,Disease in girls,Loss of speech and motor skills
How is Rett syndrome treated?
Trofinetide（Daybue）: The IGF-1 analogue, approved by the FDA in 2023, is the first approved treatment for Rett syndrome and improves some symptoms.; Gene therapy (AAV-MECP2): The AAV vector delivers the normal MECP2 gene and is currently in clinical trials.; Comprehensive rehabilitation management: Including comprehensive programs such as physical therapy, occupational therapy, speech therapy, nutritional support, and epilepsy management.
What is the prognosis for Rett syndrome?
Survive into adulthood, but severely disabled